111.67
price down icon4.25%   -4.96
pre-market  Vorhandelsmarkt:  111.01   -0.66   -0.59%
loading
Schlusskurs vom Vortag:
$116.63
Offen:
$112.43
24-Stunden-Volumen:
1.67M
Relative Volume:
1.86
Marktkapitalisierung:
$5.45B
Einnahmen:
$338.46M
Nettoeinkommen (Verlust:
$-310.96M
KGV:
-17.10
EPS:
-6.53
Netto-Cashflow:
$-132.82M
1W Leistung:
-7.22%
1M Leistung:
-12.44%
6M Leistung:
+23.38%
1J Leistung:
+45.04%
1-Tages-Spanne:
Value
$107.00
$113.73
1-Wochen-Bereich:
Value
$107.00
$122.97
52-Wochen-Spanne:
Value
$64.11
$139.13

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Name
Firmenname
Axsome Therapeutics Inc
Name
Telefon
(212) 332-3241
Name
Adresse
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
Name
Mitarbeiter
589
Name
Twitter
Name
Nächster Verdiensttermin
2025-02-18
Name
Neueste SEC-Einreichungen
Name
AXSM's Discussions on Twitter

Vergleichen Sie AXSM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
AXSM
Axsome Therapeutics Inc
111.67 5.45B 338.46M -310.96M -132.82M -6.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-11 Eingeleitet Deutsche Bank Buy
2024-12-31 Bestätigt Mizuho Outperform
2024-09-03 Eingeleitet Wells Fargo Overweight
2024-08-06 Hochstufung BofA Securities Neutral → Buy
2024-07-22 Eingeleitet Needham Buy
2024-04-29 Hochstufung Morgan Stanley Equal-Weight → Overweight
2024-03-19 Eingeleitet Robert W. Baird Outperform
2024-02-06 Eingeleitet UBS Buy
2024-01-25 Eingeleitet RBC Capital Mkts Outperform
2023-12-13 Eingeleitet Citigroup Buy
2023-08-08 Hochstufung BofA Securities Underperform → Neutral
2023-01-05 Eingeleitet Piper Sandler Neutral
2022-11-01 Eingeleitet Loop Capital Buy
2022-09-07 Fortgesetzt Mizuho Buy
2021-08-10 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-06-10 Eingeleitet Berenberg Buy
2021-01-08 Eingeleitet Jefferies Buy
2020-12-16 Eingeleitet Mizuho Buy
2020-09-29 Eingeleitet BofA Securities Underperform
2020-09-10 Eingeleitet Morgan Stanley Overweight
2020-04-28 Bestätigt H.C. Wainwright Buy
2020-04-14 Eingeleitet Cowen Outperform
2019-12-30 Bestätigt H.C. Wainwright Buy
2019-12-17 Bestätigt H.C. Wainwright Buy
2019-12-16 Bestätigt Guggenheim Buy
2019-10-16 Eingeleitet Guggenheim Buy
2019-09-18 Eingeleitet William Blair Outperform
2019-05-28 Eingeleitet SunTrust Buy
2019-05-23 Bestätigt H.C. Wainwright Buy
2019-04-08 Eingeleitet SVB Leerink Outperform
2019-03-15 Bestätigt H.C. Wainwright Buy
2016-10-03 Fortgesetzt Brean Capital Buy
2015-12-15 Eingeleitet Cantor Fitzgerald Buy
2015-12-14 Eingeleitet Ladenburg Thalmann Buy
Alle ansehen

Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten

pulisher
03:39 AM

Corient Private Wealth LLC Makes New Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

03:39 AM
pulisher
Apr 01, 2025

Axsome Plans Excessive Sleepiness Study In Depression After Phase III Failure - insights.citeline.com

Apr 01, 2025
pulisher
Apr 01, 2025

Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week - MSN

Apr 01, 2025
pulisher
Apr 01, 2025

Why Shares of Axsome Therapeutics Slumped Today - The Motley Fool

Apr 01, 2025
pulisher
Apr 01, 2025

Why Shares of Axsome Therapeutics Slumped Today - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Axsome shares fall after trial results disappoint By Investing.com - Investing.com Canada

Apr 01, 2025
pulisher
Apr 01, 2025

Axsome Must Face Securities Fraud Suit Over Migraine Drug Delays - Bloomberg Law News

Apr 01, 2025
pulisher
Apr 01, 2025

Axsome falls on depression drug's trial setback - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

Mizuho maintains Axsome stock Outperform amid trial setback - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

BofA maintains Buy rating on Axsome shares with $174 target - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Guggenheim maintains Buy on Axsome stock, price target at $195 - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Axsome's Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

Axsome Therapeutics: Promising Market Opportunity for Solriamfetol in Severe EDS Subgroup Boosts Buy Rating - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Positive Outlook for Axsome Therapeutics Amid Mixed Trial Results and Upcoming FDA Application - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

P2P Group Ltd. Investor Presentation - The Globe and Mail

Apr 01, 2025
pulisher
Apr 01, 2025

Axsome to narrow focus of depression drug trial after limited success in initial run - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Axsome stock slips as depression trial fails (AXSM:NASDAQ) - Seeking Alpha

Apr 01, 2025
pulisher
Apr 01, 2025

S&P 500 Futures Fall in Premarket Trading; Axsome Therapeutics, First Horizon Lag - MarketWatch

Apr 01, 2025
pulisher
Apr 01, 2025

Why Is Axsome Therapeutics Stock Falling In Pre-market? - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Axsome’s solriamfetol shows promise in MDD with EDS subgrou - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Axsome's depression treatment fails to meet main goal of late-stage study - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS) - Financial Post

Apr 01, 2025
pulisher
Apr 01, 2025

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of - Bluefield Daily Telegraph

Apr 01, 2025
pulisher
Apr 01, 2025

DnB Asset Management AS Has $6.24 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Apr 01, 2025
pulisher
Mar 31, 2025

Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $216.00 - MarketBeat

Mar 31, 2025
pulisher
Mar 31, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Buy" by Analysts - MarketBeat

Mar 31, 2025
pulisher
Mar 30, 2025

Loomis Sayles & Co. L P Sells 8,475 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Mar 30, 2025
pulisher
Mar 30, 2025

Axsome Therapeutics (NASDAQ:AXSM) Stock Price Down 4.9%Here's Why - MarketBeat

Mar 30, 2025
pulisher
Mar 29, 2025

Fox Run Management L.L.C. Makes New $518,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Mar 29, 2025
pulisher
Mar 29, 2025

(AXSM) Proactive Strategies - Stock Traders Daily

Mar 29, 2025
pulisher
Mar 29, 2025

Cibc World Markets Corp Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Mar 29, 2025
pulisher
Mar 27, 2025

Axsome succeeds in late-stage trial for ADHD therapy - MSN

Mar 27, 2025
pulisher
Mar 27, 2025

Celanese To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Breaking Down Axsome Therapeutics: 31 Analysts Share Their Views - Benzinga

Mar 27, 2025
pulisher
Mar 26, 2025

Medical Properties Trust : Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Bayer gains cancer drug from China’s Puhe; Axsome gets mixed ADHD data - BioPharma Dive

Mar 26, 2025
pulisher
Mar 26, 2025

AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail

Mar 26, 2025
pulisher
Mar 26, 2025

Mizuho Securities Adjusts Axsome Therapeutics Price Target to $216 From $212, Maintains Outperform Rating - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Axsome’s Sunosi succeeds in Phase III ADHD trial - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

13,460 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by HighTower Advisors LLC - MarketBeat

Mar 26, 2025
pulisher
Mar 26, 2025

Intech Investment Management LLC Acquires 5,087 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Mar 26, 2025
pulisher
Mar 25, 2025

Axsome’s latest win comes in ADHD, Opthea seeks path after AMD miss, and more: Clinical Report - biocentury.com

Mar 25, 2025
pulisher
Mar 25, 2025

Axsome’s Scores In ADHD, But Differentiation In Generic-Heavy Market Unclear - insights.citeline.com

Mar 25, 2025
pulisher
Mar 25, 2025

Axsome reports Phase 3 win for Sunosi in adults with ADHD, with a high-dose caveat - Endpoints News

Mar 25, 2025
pulisher
Mar 25, 2025

Axsome Therapeutics’ Promising Phase III FOCUS Trial Results Boost Buy Rating - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

Axsome shares fall after ADHD trial results By Investing.com - Investing.com UK

Mar 25, 2025
pulisher
Mar 25, 2025

Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

Axsome stock rises on trial win for ADHD drug (AXSM:NASDAQ) - Seeking Alpha

Mar 25, 2025
pulisher
Mar 25, 2025

Axsome Therapeutics' ADHD Trial Achieves Primary, Key Secondary Endpoints - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint - MarketScreener

Mar 25, 2025

Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Axsome Therapeutics Inc-Aktie (AXSM) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Pizzie Nick
Chief Financial Officer
Feb 14 '25
Option Exercise
3.50
3,000
10,500
45,187
Pizzie Nick
Chief Financial Officer
Feb 13 '25
Sale
129.86
12,000
1,558,320
42,187
Pizzie Nick
Chief Financial Officer
Feb 14 '25
Sale
131.07
3,000
393,210
42,187
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
Kapitalisierung:     |  Volumen (24h):